Video from AACC: Lab Ordering Cloud software
Mehdi Maghsoodnia, CEO of 1health, spoke to ScienceBoard.net's sister site LabPulse.com about the market needs for the firm’s Lab Ordering Cloud, as well as diagnostic industry trends. Read More
Studies uncover findings on antibody responses, immunity
Findings from two studies add to a growing body of knowledge that is essential for guiding public health initiatives and might one day enable clinicians to assess individuals’ immunity to SARS-CoV-2, according to AACC. Read More
Research shows heart-damaging route of SARS-CoV-2 spike protein
Researchers have demonstrated that the spike protein from the SARS-CoV-2 virus can lead to heart muscle injury through the inflammation process, according to preliminary research to be presented this week at the American Heart Association’s 2022 Basic Cardiovascular Sciences Scientific Sessions. Read More
LumiraDx to discuss microfluidic technology at AACC
LumiraDx announced that it will host an industry workshop at AACC 2022 on Wednesday, describing the impact of its microfluidic technology on lateral-flow antigen tests and the role of these rapid immunoassays in the response to the COVID-19 pandemic. Read More
Lessons from Operation Warp Speed could benefit future drug discovery
What lessons can the biotech industry learn from Operation Warp Speed? In an interview with ScienceBoard.net, Debrah Thompson, PhD, of HTG Molecular Diagnostics, discusses how the success of the COVID-19 vaccine rollout could benefit the drug discovery process going forward. Read More
Moderna, IVI join forces for vaccine research and development
Biotech giant Moderna and the International Vaccine Institute (IVI), a nonprofit inter-governmental organization headquartered in Seoul, South Korea, have signed a memorandum of understanding to collaborate on research and development for messenger RNA vaccines. Read More
Current COVID-19 boosters provide protections against serious infection: study
Despite the evolution of the SARS-CoV-2 pandemic coronavirus, a new laboratory study conducted by a team of international researchers suggests current vaccine boosters may elicit sufficient immune protection against severe omicron-induced COVID-19 disease. Read More
Connect
Science Advisory Board on LinkedIn
Science Advisory Board on Facebook
Science Advisory Board on Twitter